APA (7th ed.) Citation

H, L., GN, D., MA, M., Y, Y., S, G., M, I., . . . RM, H. (2012). VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clinical cancer research : an official journal of the American Association for Cancer Research, 18(2), 499. https://doi.org/10.1158/1078-0432.CCR-11-1625

Chicago Style (17th ed.) Citation

H, Lu, et al. "VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 18, no. 2 (2012): 499. https://doi.org/10.1158/1078-0432.CCR-11-1625.

MLA (9th ed.) Citation

H, Lu, et al. "VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 18, no. 2, 2012, p. 499, https://doi.org/10.1158/1078-0432.CCR-11-1625.